Replies to post #54221 on Amarantus Bioscience Holdings Inc (AMBS)

[DonDaDa707]

Isn't that a sad fact!?

At least in this instance it may benefit us, the AMBS stock holders.

[SpecTrader]

NuroPro Diagnostic Blood Test Platform
Amarantus Bioscience, Inc. acquired the IP behind the NuroPro test for Parkinson’s and several other indications in December 2012. A full list of indications covered is below:

Parkinson’s disease
Alzheimer’s disease
Lou Gehrig’s disease (ALS)
Neuromuscular disease
Breast Cancer
Chonic Myelogenous Leukemia

~AMBS